Atlas Venture Life Science Advisors, LLC - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 13, 2026, for the 2025 Q4 period, Atlas Venture Life Science Advisors, LLC held in its portfolio 8 assets valued at $865,154,717 (i.e. $865.16M).

The most valuable assets in the portfolio included: Kymera Therapeutics, Inc. ($362.59M), Dyne Therapeutics, Inc. ($178.59M), and Sionna Therapeutics, Inc. ($123.24M).

The chart below shows the top 8 valuable assets, and the table below shows the top 8 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in Atlas Venture Life Science Advisors, LLC Portfolio

Kymera Therapeutics, Inc.

Dyne Therapeutics, Inc.

Sionna Therapeutics, Inc.

Disc Medicine, Inc.

Day One Biopharmaceuticals, Inc.

Korro Bio, Inc.

Q32 Bio, Inc.

Generation Bio, Co.

Atlas Venture Life Science Advisors, LLC - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
Kymera Therapeutics, Inc.	4659874	362584796	Common Stock
Dyne Therapeutics, Inc.	9130465	178591895	Common Stock
Sionna Therapeutics, Inc.	2995602	123239066	Common Stock
Disc Medicine, Inc.	1513875	120216814	Common Stock
Day One Biopharmaceuticals, Inc.	6412560	59765059	Common Stock
Korro Bio, Inc.	1137149	9108563	Common Stock
Q32 Bio, Inc.	2092106	6945792	Common Stock
Generation Bio, Co.	827946	4702732	Common Stock